레지오넬라속균 검사 시장 : 검사 유형별, 용도별, 최종 용도별, 예측(2024-2032년)

Global Legionella Testing Market size will witness 8.6% CAGR between 2024 and 2032, driven by increasingly stringent water testing regulations enforced by regulatory bodies. With a significant rise in public health and safety concerns, authorities worldwide are imposing rigorous standards for Legionella detection in water systems.

For instance, in 2024, the General Services Administration (GSA) announced that it is conducting comprehensive water testing across numerous federal buildings to prioritize the health and safety of occupants and visitors. This proactive approach aids building managers in maintaining a healthy work environment. Courtney Springer, Assistant Commissioner for Facilities Management at GSA, shed light on their water testing and remediation strategies. Ensuring proper maintenance and testing of water systems is crucial to minimize the presence of heavy metals and conditions conducive to bacterial growth, including Legionella. This effort is particularly vital for large buildings, such as many GSA facilities, and those with unique features like decorative fountains or cooling towers.

This has led to a surge in demand for testing services and solutions capable of accurately identifying the bacteria. As regulatory scrutiny intensifies, the market for Legionella testing continues to grow, reflecting a concerted effort to ensure water quality and mitigate the risk of Legionnaires' disease outbreaks.

The overall Legionella Testing Market is classified based on the test type, application, end-user, and region.

The urinary antigen test segment will undergo significant development from 2024 to 2032. This approach offers a rapid and reliable means of detecting Legionella bacteria, particularly in cases of Legionnaires' disease. Urinary antigen testing has emerged as a preferred diagnostic tool for its convenience and efficiency, driving demand for testing services and solutions. As healthcare providers increasingly rely on this method for timely diagnosis and treatment, the Legionella Testing Market continues to expand to meet the growing need for effective testing solutions.

The legionella testing market share from the in vitro diagnostics testing segment will register a noteworthy CAGR from 2024 to 2032. These advanced diagnostic techniques offer accurate and efficient detection of Legionella bacteria crucial in preventing Legionnaires' disease outbreaks. In vitro diagnostics testing provides healthcare professionals with timely and reliable results, facilitating prompt treatment and containment efforts. As the importance of early detection grows, so does the demand for in vitro diagnostics testing solutions, fueling the expansion of the Legionella Testing Market to meet evolving healthcare needs.

Europe legionella testing market will showcase a commendable CAGR from 2024 to 2032. With a focus on public health and safety, European countries are increasingly implementing comprehensive testing protocols for water systems in various settings, including healthcare facilities, commercial buildings, and industrial sites.

This increased emphasis on preventive measures and early detection is fueling the demand for Legionella testing services and products across the region, driving growth in the Legionella Testing Market. For instance, in August 2023, an investigation was initiated in Poland after Legionella bacteria was detected in the water supply of Rzeszow, a city in the southeastern region. The country's counterintelligence agency, ABW, looked into the possibility of intentional contamination, and as a precautionary step, Rzeszow undertook disinfection measures for its water supply system.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of pneumonia and legionella related illnesses
    • 3.2.1.2 Rapid advancements in legionella testing
    • 3.2.1.3 Stringent regulations for regular water testing
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High costs associated with testing procedures
    • 3.2.2.2 Issues in sensitivity of diagnostic tests
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Test Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Culture methods
• 5.3 Urinary antigen test (UAT)
• 5.4 Serology
• 5.5 Direct fluorescent antibody test (DFA)
• 5.6 Polymerase chain reaction (PCR) testing
• 5.7 Other test types

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Water testing
  • 6.2.1 Microbial culture
  • 6.2.2 DFA stain
  • 6.2.3 PCR
• 6.3 Invitro diagnostics (IVD) testing
  • 6.3.1 Blood culture and sputum tests
  • 6.3.2 Urinary antigen tests
  • 6.3.3 DFA stain
  • 6.3.4 PCR
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital and clinics
• 7.3 Water treatment plants
• 7.4 Diagnostic laboratories
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Argentina
  • 8.5.3 Mexico
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Becton, Dickinson & Company
• 9.3 Biomerieux
• 9.4 Bio-Rad Laboratories Inc.
• 9.5 Danaher Corporation
• 9.6 IDEXX Laboratories Inc
• 9.7 Merck KGaA
• 9.8 Pro-lab Diagnostics Inc.
• 9.9 QIAGEN N.V.
• 9.10 Thermo Fisher Scientific Inc.